Hepatitis/MASH

Bill authorizes the VA to spend as much as $500 million for hepatitis C treatments.

Comorbidities lead to more complex treatment and higher costs.

Additional benefit from dasabuvir and combination of ombitasvir/paritaprevir/ritonavir found in pretreated genotype 1b hepatitis C patients without cirrhosis.

Hepatitis C drugs with high cure rates create new dilemma for people in need of transplantation.

A lymphotoxin-beta receptor inhibitor may stop the spread of the disease.

Single-tablet combination was previously granted two breakthrough therapy designations.

The FDA has granted priority review to Merck's chronic hepatitis C virus (HCV) treatment candidate grazoprevir/elbasvir.

Liver damage progresses at a more rapid pace in patients with HIV.

Sofosbuvir-based therapy offers the potential for high cure rates even in difficult-to-treat patient groups.

Treatment regimen was previously approved for 12 weeks in patients without cirrhosis or 24 weeks in those with cirrhosis.

A relationship between hepatitis C and cancer is reinforced by data from epidemiologic research.

David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses takeaways from the impact of high cost drug launches on specialty pharmacy.

Janssen is asking the FDA to update the label of its once-daily hepatitis C virus (HCV) drug simeprevir (Olysio).

Technivie with ribavirin is the first drug to demonstrate safety and efficacy in genotype 4 infections without interferon.

Company alleges insurers are taking advantage of program to shift cost of Sovaldi.

New procedure seeks to guide therapeutic decisions.

Drug cost mitigated by savings in health care costs on management of conditions that may result from chronic hepatitis C virus.

Treating hepatitis C patients who receive health care through Medicaid with Sovaldi could exceed $55 billion.

Combination of grazoprevir and elbasvir has been studied in patients with genotype 1 hepatitis C who also have end-stage renal disease and are undergoing regular hemodialysis.

Shorter duration could reduce the economic impact on health care spending and make treatment more convenient.

New culturing method leads to highly therapeutic cells that grow faster and stronger.

Envarsus protects against organ rejection in transplant patients who switch from other twice-daily tacrolimus products.

Includes evidence-based advice on the best use for next generation direct-acting antivirals.

Here are new drugs for 2015 that pharmacists can expect to handle.

Exchange plan spending on hepatitis C drugs increased 96% in the first quarter of 2015.